Abstract
This study explores the manifestation and measurement of anxiety symptoms in 415 children with ASDs on a 20-item, parent-rated, DSM-IV referenced anxiety scale. In both high and low-functioning children (IQ above vs. below 70), commonly endorsed items assessed restlessness, tension and sleep difficulties. Items requiring verbal expression of worry by the child were rarely endorsed. Higher anxiety was associated with functional language, IQ above 70 and higher scores on several other behavioral measures. Four underlying factors emerged: Generalized Anxiety, Separation Anxiety, Social Anxiety and Over-arousal. Our findings extend our understanding of anxiety across IQ in ASD and provide guidance for improving anxiety outcome measurement.
Similar content being viewed by others
Abbreviations
- ASDs:
-
Autism spectrum disorders
- PDD:
-
Pervasive developmental disorder
- RUPP:
-
Research Units in Pediatric Psychopharmcology
- STAART:
-
Studies to Advance Autism Research and Treatment
- CYBOCS-PDD:
-
Children’s Yale-Brown Obsessive Compulsive Scales modified for Pervasive Developmental Disorders
References
Aman, M. G., McDougle, C. J., Scahill, L., Handen, B., Arnold, L. E., Johnson, C., et al. (2009). Medication and parent training in children with pervasive developmental disorders and serious behavior problems: Results from a randomized clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry, 48(12),1143–1154.
Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985). The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects. American journal of mental deficiency, 89(5), 485–491.
American Psychiatric Association. (1980). Diagnostic and statistical manual of mental disorders (3rd ed.). Washington, DC: American Psychiatric Association.
American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: American Psychiatric Association.
Brown, E. C., Aman, M. G., & Havercamp, S. M. (2002). Factor analysis and norms for parent ratings on the Aberrant Behavior Checklist-Community for young people in special education. Research in Developmental Disabilities, 23(1), 45–60.
Browne, M. W., Cudeck, R., Tateneni, K., & Mels, G. (2009). CEFA: Comprehensive exploratory factor analysis, version 3.04. [Computer Software and Manual].
Canitano, R. (2006). Self injurious behavior in autism: Clinical aspects and treatment with risperidone. Journal of neural transmission, 113(3), 425–431.
Costello, E. J., Egger, H. L., & Angold, A. (2005). The developmental epidemiology of anxiety disorders: Phenomenology, prevalence, and comorbidity. Child and adolescent psychiatric clinics of North America, 14(4), 631–648.
Gadow, K. D., DeVincent, C. J., Pomeroy, J., & Azizian, A. (2004). Psychiatric symptoms in preschool children with PDD and clinic and comparison samples. Journal of Autism and Developmental Disorders, 34(4), 379–393.
Gadow, K. D., Devincent, C. J., Pomeroy, J., & Azizian, A. (2005). Comparison of DSM-IV symptoms in elementary school-age children with PDD versus clinic and community samples. Autism: The International Journal of Research and Practice, 9(4), 392–415.
Gadow, K. D., & Sprafkin, J. (1998). Adolescent symptom inventory-4 norms manual (Vol. Stony Brook, NY: Checkmate Plus). Stony Brook, NY: Checkmate Plus.
Gadow, K. D., & Sprafkin, J. (2002). Child symptom inventory-4 screening and norms manual. Stony Brook, NY: Checkmate Plus.
Goodman, W. K., Price, L. H., Rasmussen, S. A., Mazure, C., Fleischmann, R. L., Hill, C. L., et al. (1989). The yale-brown obsessive compulsive scale: 1. Development, use, and reliability. Archives of General Psychiatry, 46(11), 1006–1011.
Ivarsson, T., & Melin, K. (2008). Autism spectrum traits in children and adolescents with obsessive-compulsive disorder (OCD). Journal of Anxiety Disorders, 22(6), 969–978.
Jensen, J. A., & Armstrong, R. J. (1985). Slosson intelligence test for children and adults. East Aurora, NY: Slosson Educational Publications.
Jöreskog, K. G., & Sörbom, D. (2004). LISREL 8.7 for Windows [Computer Software]. Lincolnwood, IL: Scientific Software International, Inc.
Kanner, L. (1943). Autistic disturbances of affective contact. Nervous Child, 2(3), 217–250.
Kim, J. A., Szatmari, P., Bryson, S. E., Streiner, D. L., & Wilson, F. J. (2000). The prevalence of anxiety and mood problems among children with autism and Asperger syndrome. Autism: The International Journal of Research and Practice, 4(2), 117–132.
King, B. H., Hollander, E., Sikich, L., McCracken, J. T., Scahill, L., Bregman, J. D., et al. (2009). Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: Citalopram ineffective in children with autism. Archives of General Psychiatry, 66(6), 583–590.
Le Couteur, A., Lord, C., & Rutter, M. (2003). Autism diagnostic interview-revised. Los Angeles: Western Psychological Services.
Lecavalier, L. (2006). Behavioral and emotional problems in young people with pervasive developmental disorders: Relative prevalence, effects of subject characteristics, and empirical classification. Journal of Autism and Developmental Disorders, 36(8), 1101–1114.
Marshburn, E. C., & Aman, M. G. (1992). Factor validity and norms for the aberrant behavior checklist in a community sample of children with mental-retardation. Journal of Autism and Developmental Disorders, 22(3), 357–373.
Mazurek, M. O., & Kanne, S. M. (2010). Friendship and internalizing symptoms among children and adolescents with ASD. Journal of Autism and Developmental Disorders, 40(12), 1512–1520.
McDougle, C. J., Scahill, L., Aman, M. G., McCracken, J. T., Tierney, E., Davies, M., et al. (2005). Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. The American journal of psychiatry, 162(6), 1142–1148.
Mullen, E. (1995). Mullen scales of early learning. Circle Pines, MN: American Guidance Service.
Pine, D. S., Guyer, A. E., Goldwin, M., Towbin, K. A., & Leibenluft, E. (2008). Autism spectrum disorder scale scores in pediatric mood and anxiety disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 47(6), 652–661.
Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. (2002). Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine, 347(5), 314–321.
Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. (2005). Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Archives of General Psychiatry, 62(11), 1266–1274.
Roid, G. H., & Miller, L. J. (1997). Leiter international performance scale-revised. Wood Dale, IL: Stoelting.
Scahill, L., McCracken, J. T., Bearss, K., Robinson, F., Hollander, E., King, B., et al. (2012). Design and subject characteristics in the federally-funded citalopram trial in children with pervasive developmental disorders. Journal of Autism and Developmental Disorders, 42(3), 432–440.
Scahill, L., McDougle, C. J., Williams, S. K., Dimitropoulos, A., Aman, M. G., McCracken, J. T., et al. (2006). Children’s yale-brown obsessive compulsive scale modified for pervasive developmental disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 45(9), 1114–1123.
Scahill, L., Riddle, M. A., McSwiggin-Hardin, M., Ort, S. I., King, R. A., Goodman, W. K., et al. (1997). Children’s yale-brown obsessive compulsive scale: Reliability and validity. Journal of the American Academy of Child and Adolescent Psychiatry, 36(6), 844–852.
Sparrow, S. S., Balla, D. A., & Cicchetti, D. V. (1984). Vineland adaptive behavior scales. Circle Pines, MN: American Guidance Service.
Sprafkin, J., Gadow, K. D., Salisbury, H., Schneider, J., & Loney, J. (2002). Further evidence of reliability and validity of the Child Symptom Inventory-4: Parent checklist in clinically referred boys. Journal of Clinical Child and Adolescent Psychology, 31(4), 513–524.
Sukhodolsky, D. G., Scahill, L., Gadow, K. D., Arnold, L. E., Aman, M. G., McDougle, C. J., et al. (2008). Parent-rated anxiety symptoms in children with pervasive developmental disorders: Frequency and association with core autism symptoms and cognitive functioning. Journal of Abnormal Child Psychology, 36(1), 117–128.
van Steensel, F. J., Bogels, S. M., & Perrin, S. (2011). Anxiety disorders in children and adolescents with autistic spectrum disorders: A meta-analysis. Clinical child and family psychology review. 14(3), 302–317.
Wechsler, D. (1989). Wechsler preschool and primary scale of intelligence-revised. San Antonio, TX: The Psychological Corporation.
Wechsler, D. (1991). Wechsler intelligence scale for children (3rd ed.). San Antonio, TX: The Psychological Corporation.
Weisbrot, D. M., Gadow, K. D., DeVincent, C. J., & Pomeroy, J. (2005). The presentation of anxiety in children with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 15(3), 477–496.
White, S. W., Oswald, D., Ollendick, T., & Scahill, L. (2009). Anxiety in children and adolescents with autism spectrum disorders. Clinical Psychology Review, 29(3), 216–229.
Witwer, A. N., & Lecavalier, L. (2010). Validity of comorbid psychiatric disorders in youngsters with autism spectrum disorders. Journal of Developmental and Physical Disabilities, 22(4), 367–380.
Acknowledgments
The authors acknowledge Ann Wagner, PhD and Louise Ritz, MBA at NIMH; James Robinson, MED, at NKI; Mark Davies, MPH at NY State Psychiatric Institute, Stacey Grinnon, MA at KAI Research, Inc; Deborah Hirtz MD at the National Institute of Neurological Disorders and Stroke, Bethesda, Lisa Sullivan, PhD at Boston University; Fay Robinson, MPH at DMSTAT and James Dziura, PhD, Sunkyung Yu, MS, Yanhong Deng, MPH and Allison Gavaletz, BS at Yale University. The RUPP studies were funded by the following NIMH grants and contracts: N01MH70009 and U10MH66764 (Yale); N01MH70001 and U10MH66766 (Indiana University); N01MH80011 and U10MH66768 (Ohio State University); N01MH70010 (UCLA). This publication was also supported by the Yale Clinical and Translational Science Award (CTSA) UL1RR024139, Indiana University CTSA UL1 RR025761, and Ohio State University CTSA UL1 RR025755 from the National Center for Research Resources (NCRR). The STAART citalopram study was funded by NIH via the following center contracts: Mount Sinai School of Medicine: U54-MH066673; University of North Carolina at ChapelHill: U54-MH066418; University of California at Los Angeles: U54-MH068172; Yale University: U54-MH066494. Dartmouth Medical School and Boston University: U54-MH066398; and DM-STAT, Inc, Boston: U01-HD045023.
Conflict of interest
Dr. Scahill: Roche, consultant; Pfizer, consultant; Bracket, consultatnt, BioMarin, consultant. Shire, research support; Roche, research support; Pfizer, research support. Dr. Aman: Roche, consultant; Bristol-Meyers Squibb, consultant, research grant; Forest, consultant; Pfizer, consultant; Supernus, consultant; Johnson & Johnson, research grant. Dr. Gadow: Checkmate Plus, publisher of the Child and Adolescent Symptom Invetory-4; Dr. McDougle: Bristol-Myers Squibb, research grant, speaker’s bureau. Dr. McCracken: salary from UCLA, research support from NIH, Seaside Therapeutics, Roche, and Otsuka; consultant income from Novartis, BioMarin, PharmaNet, and Noven; speaker’s honoraria from the Tourette Syndrome Association; and research study drug supply from Shire; Dr. Arnold: AstraZeneca, advisory board; Biomarin, advisory board; CureMark, research funding; Lilly, research funding; Noven, advisory board; Seaside therapeutics, advisory board; Shire, research funding. Dr. Tierney: BioMarin, consultant. Dr. Donnelly: consultant for Eli Lilly Pharmaceutical Company, Abbott Pharmaceutical Company and Shire Pharmaceuticals. He has served on the Speaker’s Bureau for Eli Lilly, and Shire. He has received research funding from Eli Lilly. Dr. Hollander reports serving as a consultant to Neuropharm. Dr. King reports serving as a consultant to Biomarin and Neuropharm and as an unpaid consultant to Forest, Nastech, and Seaside Therapeutics. He has received or has pending research grant support from Neuropharm and Seaside Therapeutics. Dr. Sikich has received support from Bristol Myers Squibb and Pfizer, participated in clinical trials sponsored by Neuropharm, Curemark, Seaside Pharmaceuticals, and recieved medications or software Janssen Pharmaceutica, Eli Lilly, Pfizer, Bristol Myers Squibb and Positscience. Dr. Hallett, Dr. Lecavalier, Dr. Sukhodolsky, Dr. Vitiello, Ms Katsovich Dr. Anagnostou, Dr. Bregman, and Dr. Dukes report no financial relationships with commercial interests.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hallett, V., Lecavalier, L., Sukhodolsky, D.G. et al. Exploring the Manifestations of Anxiety in Children with Autism Spectrum Disorders. J Autism Dev Disord 43, 2341–2352 (2013). https://doi.org/10.1007/s10803-013-1775-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10803-013-1775-1